CureVac NV

( )
CVAC After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Major
PFEPfizer Inc. 0.86%52.990.9%$1958.03m
JNJJohnson & Johnson 0.42%168.340.7%$1218.17m
ABBVAbbVie, Inc. 0.84%134.211.9%$1007.72m
MRKMerck & Co., Inc. -0.40%79.140.7%$922.99m
BMYBristol-Myers Squibb Co. -0.38%62.221.0%$707.05m
LLYEli Lilly & Co. -0.81%237.511.1%$629.80m
AZNAstraZeneca Plc -1.26%57.121.0%$260.90m
NVSNovartis AG -0.36%84.240.2%$193.64m
GSKGlaxoSmithKline Plc -0.50%44.150.2%$185.72m
NVONovo Nordisk A/S -2.14%93.120.1%$158.88m
VTRSViatris, Inc. -0.41%14.620.0%$135.93m
RGENRepligen Corp. -2.07%181.566.7%$101.32m
BHVNBiohaven Pharmaceutical Holding Co. Ltd. 8.52%126.250.0%$96.48m
SNYSanofi -0.16%51.320.2%$69.31m
RPRXRoyalty Pharma Plc -0.51%38.930.1%$63.78m

Company Profile

CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). Its product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology, and protein therapy. The company was founded by Ingmar Hoerr and Florian von der Mülbe in 2000 and is headquartered in Tübingen, Germany.